GlassScriptPhysician profile
Steven W Queen
NPI 1760440812
$11,165.41
in general payments reported to CMS, 2019-2025
38 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,193 · 2020: $625 · 2021: $1,504 · 2022: $2,380 · 2023: $2,073 · 2024: $1,231 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,608.24 | 2019-2025 | |
| Novo Nordisk INC | $1,283.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,038.84 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $882.33 | 2019-2025 | Otezla, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $785.45 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $615.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $571.46 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $554.34 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $510.36 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.30 | 2019-2024 | Jardiance, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $457.51 | 2019-2025 | Trintellix, Takhzyro |
| Merck Sharp & Dohme LLC | $319.30 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $317.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $176.33 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.11 | 2021-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $133.56 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $121.91 | 2019-2024 | Eliquis |
| Dexcom, INC. | $110.62 | 2021-2025 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $104.34 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Otsuka America Pharmaceutical, INC. | $93.35 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $86.74 | 2022-2024 | Veozah |
| Paratek Pharmaceuticals, INC. | $86.30 | 2023-2024 | Nuzyra |
| Viatris Specialty LLC | $86.24 | 2025 | Yupelri |
| Medtronic, INC. | $76.10 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $74.52 | 2020-2021 | |
| Csl Behring | $64.53 | 2022 | |
| Amarin Pharma, INC. | $61.08 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.63 | 2022 | |
| Allergan, INC. | $42.09 | 2019-2020 | |
| Exact Sciences Corporation | $38.76 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $32.57 | 2022-2023 | Quviviq |
| Biocryst US Sales Co., LLC | $26.66 | 2022 | |
| Medtronic Minimed, INC. | $23.30 | 2019 | |
| Almatica Pharma LLC | $21.30 | 2022 | |
| Nevro Corp. | $17.97 | 2022 | |
| Eisai INC. | $16.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.77 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Queen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.